Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

145.20 +0.36 (+0.25%)
Official Closing Price Updated: 7:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
29 30 Next >
Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products
MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
10 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option... 
Via Benzinga
Former Tilray CEO Joins Psychedelics Company
More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
AbbVie Touts Additional Rinvoq Data In Inflammatory Spinal Arthritis
AbbVie Inc (NYSE: ABBV) has churned out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor's megablockbuster potential.... 
Via Benzinga
3 DRIP Stocks With 4% Yields
If dividend stocks provide investors with predictable income, then DRIP stocks offer significant long-term growth potential. 
Via Talk Markets
Why AbbVie Stock Sank in September
A regulatory setback weighed on the drugmaker's shares last month. 
Via The Motley Fool
Exposures Product Safety
Best Pharmaceutical Stocks To Buy In 2021
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars. 
Via Talk Markets
Biohaven Surges To Record High As Kardashian-Backed Migraine Drug Outperforms — Again
This company sells a migraine medicine backed by Khloe Kardashian. 
Via Investor's Business Daily
September Ends
Congress managed to pass a bipartisan short-term spending bill avoiding a crisis over the debt ceiling. 
Via Talk Markets
AbbVie Presents New Upadacitinib Data In Atopic Dermatitis
AbbVie Inc (NYSE: ABBV) announced new analyses from the Phase 3 Rinvoq (upadacitinib) atopic dermatitis clinical trial program. Data were presented at the European... 
Via Benzinga
AbbVie Unveils New Durable Risankizumab Data In Psoriatic Arthritis
AbbVie Inc (NYSE: ABBV) announced new Phase 3 data analyses of KEEPsAKE-1 and KEEPsAKE-2, evaluating Skyrizi (risankizumab) in adults with active psoriatic... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
I-Mab In Talks With Pharma Giants About Partnership, Stake Sale: Bloomberg
A year after I-Mab (NASDAQ: IMAB) made headlines with its $2.9 billion deal licensing a CD47 drug to AbbVie Inc (NYSE: ABBV), the biotech is reportedly... 
Via Benzinga
FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie
The FDA has approved AbbVie Inc's (NYSE: ABBV) Qulipta (atogepant) to prevent episodic migraines in adults. Qulipta is the first and only oral calcitonin gene-... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors
The well-known pharmaceutical company is a portfolio stalwart. 
Via The Motley Fool
This Dividend Aristocrat Is Dirt-Cheap And Pays A Market-Smashing Yield
With a market-smashing yield near 5%, a moderate payout ratio, a dividend growth legacy that dates back decades, double-digit long-term dividend growth, and the potential that shares are 15%... 
Via Talk Markets
Could AbbVie's New Collaboration Be a Blockbuster?
AbbVie recently announced a strategic partnership with Regenxbio for wet age-related macular degeneration and diabetic retinopathy treatment. 
Via The Motley Fool
Barron's Latest Picks And Pans: Healthcare Roundtable Picks, Dividend Aristocrats And More
This weekend's Barron's cover story offers 10 stock picks from the 2021 Barron's healthcare roundtable. Other featured articles discuss how COVID-19 has affected... 
Via Benzinga
Exposures COVID-19
Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal
The big drugmaker wants another near-term growth driver. 
Via The Motley Fool
Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug
In a spat between Takeda Pharmaceutical Co Ltd (NYSE: TAK) and AbbVie Inc (NYSE: ABBV) for Lupron (leuprorelin), a Delaware judge has issued a ruling in... 
Via Benzinga
3 Relatively Safe Pharma Stocks You Can Buy Right Now
These stocks should be less volatile than many of the alternatives. 
Via The Motley Fool
AbbVie Is Worth 28% More Based on Impressive Dividends
AbbVie is still cheap despite its gains. ABBV stock trades for under 8 times next year's EPS and a 5.3% yield, making it 28.5% undervalued. 
Via InvestorPlace
Is AbbVie a Bad News Buy?
Probably so -- for some investors. 
Via The Motley Fool
Exposures Product Safety
AbbVie's Pain Is Sanofi's and Regeneron's Gain
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors. 
Via The Motley Fool
Exposures Product Safety
Look For The Q4 Biotech Bounce In Mid-Small Caps
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best... 
Via Talk Markets
40 Consistent Attractively Valued Dividend Growth Stocks
hese companies have consistent long-term operating history and solid prospects for future growth. 
Via Talk Markets
AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis
AbbVie Inc (NYSE: ABBV) has submitted applications seeking approval for upadacitinib (15 mg and 30 mg (maintenance dose) and 45 mg (induction dose)) for active... 
Via Benzinga
25 Best & 10 Cheapest Dividend Aristocrats
These are blue-chip dividend-paying stocks that have increased their dividend for at least 25 consecutive years or longer. 
Via Talk Markets
Is AbbVie's 4.9% Dividend Yield Safe?
Should investors pick up the stock after its recent sell-off? 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.